# Oncimmune Holdings plc Appoint Marco Casarin as General Manager, Oncimmune USA

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-appoint-marco-casarin-as-general-manager-oncimmune-usa/412758379
- Published: 2018-09-13T07:07:14+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® liquid biopsy platform technology,
today announced the appointment of Marco Casarin as General Manager, Oncimmune USA
LLC.

Marco has more than 25 years of global healthcare experience particularly within
large and multinational lab and diagnostic services companies. Marco was most recently
at Thermo Fisher Scientific Inc and previously his roles have included senior commercial,
marketing and operational roles at Roche Diagnostics and Vela Diagnostics, which
he also co-founded.

> **Geoffrey Hamilton-Fairley, CEO of Oncimmune Holdings plc, commented:** “Marco’s
> deep expertise in the diagnostics industry speaks for itself. His experience will
> be invaluable as we continue to develop our US market strategies for our core 
> products EarlyCDT®-Lung and EarlyCDT®-Liver. We are confident that he will ensure
> we continue to deliver the commercial potential of our proven autoantibody-based
> blood tests.”
> **Commenting on his appointment, Marco Casarin, said:** “In EarlyCDT®-Lung, Oncimmune
> has a simple, highly accurate and extensively studied blood test that can help
> physicians, and especially pulmonologists, assess patients at high risk of lung
> cancer and also optimise assessment of malignancy risk in intermediate-risk lung
> nodules. I very much look forward to working with the rest of the team to build
> on the commercial platform and bring the benefits of Oncimmune’s tests to more
> clinicians and patients.”

In addition, Oncimmune has expanded its commercial team with the appointment of 
two new Clinical Sales Specialists, Ken Shubert and Charles Kang, to advance adoption
and increase sales of EarlyCDT® tests in the Northeast and Midwest regions of the
United States.

Share on:
